| アブストラクト | AIM: This study aimed to systematically characterize transplant rejection after immune checkpoint inhibitors (ICIs) initiation in solid organ transplant recipients (SOTRs). METHODS: Data were extracted from the US FDA Adverse Event Reporting System (FAERS) database and case reports in the literature. Disproportionality analysis including information component and reported odds ratio (ROR) was performed to access potential risk signals. RESULTS: A total of 168 patients with transplant rejection after ICIs usage were identified in the FAERS database, and 89 cases were identified in the literature review. ICIs were significantly associated with transplant rejection (ROR(025) : 2.2). A strong risk signal was found for combination therapy with pembrolizumab and ipilimumab compared to monotherapy. CONCLUSION: Immune checkpoint inhibitors were significantly associated with transplant rejection in SOTRs. |
|---|
| ジャーナル名 | Cancer medicine |
|---|
| Pubmed追加日 | 2022/12/13 |
|---|
| 投稿者 | Cui, Xiangli; Yan, Cilin; Xu, Ye; Li, Dandan; Guo, Mingxing; Sun, Liying; Zhu, Zhijun |
|---|
| 組織名 | Pharmacy Department of Beijing Friendship Hospital, Capital Medical University,;Beijing, China.;Liver Transplantation Center, Beijing Friendship Hospital, Capital Medical;University, Beijing, China.;School of Automation Science and Electrical Engineering, Beihang University, |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36504294/ |
|---|
